Beranda › Neoplasma Mieloproliferatif › Texas › Houston
Uji klinis Neoplasma Mieloproliferatif di Houston, TX
16 studi untuk Neoplasma Mieloproliferatif mencari peserta di lokasi sekitar Houston (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Menerima pesertaFase 1
- The University of Texas, MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Menerima pesertaStudi observasional
- Texas Children's Hospital, Houston
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Menerima pesertaFase 2
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- Ben Taub General Hospital, Houston
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Menerima pesertaFase 1/2
- MD Anderson, Houston
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Menerima pesertaFase 1
- M D Anderson Cancer Center, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Menerima pesertaFase 2
- The University of Texas MD Anderson Cancer Center, Houston
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Menerima pesertaFase 1/2
- M D Anderson Cancer Center, Houston
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Menerima pesertaFase 2
- M D Anderson Cancer Center, Houston
Project: Every Child for Younger Patients With Cancer
Menerima pesertaStudi observasional
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
- UT MD Anderson Cancer Center, Houston
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Menerima pesertaFase 1
- University of Texas M. D. Anderson Cancer Center, Houston
Asciminib Roll-over Study
Menerima pesertaFase 4
- Uni Of TX MD Anderson Cancer Cntr, Houston
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Menerima pesertaFase 2
- M D Anderson Cancer Center, Houston
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Menerima pesertaFase 1
- Md Anderson Cancer Center, Houston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
Menerima pesertaFase 2
- MD Anderson, Houston
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Menerima pesertaStudi observasional
- Massive Bio SYNERGY-AI site, Houston
Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs
Menerima pesertaFase 1
- The University of Texas MD Anderson Cancer Center, Houston
Uji klinis Neoplasma Mieloproliferatif di kota lain
- New York City, NY15 studi
- Boston, MA14 studi
- Milwaukee, WI10 studi
- Miami, FL10 studi
- Chicago, IL9 studi
- Durham, NC9 studi
- Baldwin Park, CA9 studi
- Seattle, WA9 studi
- Atlanta, GA8 studi
- Tampa, FL8 studi
- Birmingham, AL8 studi
- Columbus, OH8 studi
Studi lain di Houston
- Kanker Paru Non-Sel Kecil145 studi
- Kanker Payudara126 studi
- Kanker (semua jenis)121 studi
- Kanker Metastatik104 studi
- Kanker Kolorektal102 studi
- Kanker Ovarium89 studi
- Leukemia Mieloid Akut85 studi
- Kanker Paru78 studi
- Kanker Prostat76 studi
- Kanker Endometrium68 studi
- Kanker Pankreas61 studi
- Melanoma59 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.